Biogen Acquires Apellis for .6 Billion, Building Immunology Empire
140% Premium Signals Aggressive Pivot Beyond Neurology for Multiple Sclerosis Pioneer
Biogen has agreed to pay at least .6 billion to acquire fellow Massachusetts biotech Apellis Pharmaceuticals in a deal that marks a dramatic strategic pivot beyond the company neuroscience roots.
Deal Structure
- Cash price: per share (140% premium to closing price)
- Additional value: Non-transferable CVRs worth up to per share
- Products gained: Syfovre (geographic atrophy) and Empaveli (rare blood/kidney disorders)
- Apellis focus: Inhibiting C3 protein in the complement immune system
The Science
Apellis researches the complement system, the body first line of defense against pathogens. When overactive, it attacks healthy tissues, causing diseases ranging from eye disorders to rare blood conditions. Apellis drugs specifically inhibit C3, the central component.
Products
- Syfovre: Treats geographic atrophy, an eye disease where an overactive complement system damages retinal cells
- Empaveli: Used for rare disorders affecting blood and kidneys
Strategic Rationale
Biogen CFO Robin Kramer noted the importance of bringing two early commercial assets into the portfolio. The deal also provides a team with nephrology expertise that will support Biogen upcoming launch of felzartamab for rare kidney diseases.
Analysts at Stifel called the deal surprising but strategically sensible given Biogen interest in rare kidney diseases and non-neurology specialty drug markets.
Broader Context
The Apellis deal follows Eli Lilly .3 billion Centessa buyout, both using CVR structures to bridge valuation gaps between buyers and sellers. This emerging deal structure is becoming the preferred tool in biotech M&A.
Source: BioPharma Dive https://www.biopharmadive.com/news/biogen-apellis-acquisition-deal-immune-syfovre-empaveli/816233/